Published in Mol Cancer Ther on August 01, 2007
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy. Cell Death Dis (2014) 1.05
Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol (2014) 0.96
Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. Int J Radiat Biol (2012) 0.85
β-irradiation (¹⁶⁶Ho patch)-induced skin injury in mini-pigs: effects on NF-κB and COX-2 expression in the skin. J Vet Sci (2014) 0.81
Ascorbic acid attenuates antineoplastic drug 5-fluorouracil induced gastrointestinal toxicity in rats by modulating the expression of inflammatory mediators. Toxicol Rep (2015) 0.76
Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis. Curr Ther Res Clin Exp (2012) 0.75
Therapeutic effect of topical application of curcumin during treatment of radiation burns in a mini-pig model. J Vet Sci (2016) 0.75
Derlin-1 is a target to improve radiotherapy effect of esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One (2017) 0.75
Mucoadhesive formulation of Bidens pilosa L. (Asteraceae) reduces intestinal injury from 5-fluorouracil-induced mucositis in mice. Toxicol Rep (2015) 0.75
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00
Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00
Systematic review: anal and rectal changes after radiotherapy for prostate cancer. Int J Colorectal Dis (2013) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs (2008) 0.93
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93
Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care (2009) 0.93
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer (2014) 0.92
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol (2012) 0.91
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer (2014) 0.89
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
Biomarkers of regimen-related mucosal injury. Cancer Treat Rev (2011) 0.87
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85
Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer (2007) 0.85
Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol (2009) 0.85
Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer (2014) 0.85
Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. Exp Biol Med (Maywood) (2013) 0.84
The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol (2002) 0.84